PhoenixBio Co., Ltd. (JP:6190)

:6190

6190

PhoenixBio Co., Ltd.

RESEARCH TOOLSreports

Want to see JP:6190 full AI Analyst Report?

PhoenixBio Co., Ltd. (6190) Price & Analysis

0 Followers

6190 Stock Chart & Stats

¥484.00

¥9.00(2.79%)

At close: Jan 08 4:00 PM EST

¥484.00

¥9.00(2.79%)

Day’s Range― - ―

52-Week Range¥363.00 - ¥724.00

Previous CloseN/A

Volume3.50K

Average Volume (3M)360.67K

Market Cap

¥1.49B

Enterprise Value¥1.06B

Total Cash (Recent Filing)¥1.04B

Total Debt (Recent Filing)¥503.59M

Price to Earnings (P/E)11.9

Beta0.55

Next Earnings

Aug 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-112.33

Shares Outstanding4,076,933

10 Day Avg. Volume91,460

30 Day Avg. Volume360,670

Financial Highlights & Ratios

PEG Ratio-0.11

Price to Book (P/B)1.15

Price to Sales (P/S)1.14

P/FCF Ratio31.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross Margins & Profitability ReboundA sustained ~76% gross margin and recent return to profitability indicate structural pricing power and low direct costs in its niche animal-supply business. That margin buffer supports reinvestment and resilience through cycles, helping sustain earnings when volumes are stable.

Improving Balance Sheet And LeverageLower leverage (D/E ~0.31) and a return to positive ROE signal better financial flexibility versus prior years of stress. A healthier capital structure reduces interest burden and preserves capacity to fund operations or targeted investments without immediate refinancing pressure.

Niche Market Position In Preclinical ModelsFocus on specialized disease-model animals and related services creates high entry barriers and customer stickiness from pharma and research institutes. This niche generates recurring demand and long product lifecycles, underpinning steady structural revenue streams over months to years.

Bears Say

Inconsistent Cash GenerationRepeated years of negative operating and free cash flow, with only modest positive OCF in 2026 that covers ~0.18x of earnings, indicate earnings have not reliably converted to cash. This limits self-funded growth, increases financing risk, and weakens long-term resilience.

Earnings Volatility And CyclicalityMulti-year swings between sizable profits and losses demonstrate structural revenue and margin volatility. Such cyclicality hampers forecasting, capital allocation, and customer planning, and raises the execution risk of sustaining recent margin improvements over a full cycle.

Limited Scale And Capital BaseA small workforce and modest equity base constrain scale economies, R&D capacity, and ability to diversify client exposure. Limited scale makes it harder to compete with larger CROs, absorb demand shocks, or invest heavily in new service lines without external funding.

6190 FAQ

What was PhoenixBio Co., Ltd.’s price range in the past 12 months?

PhoenixBio Co., Ltd. lowest stock price was ¥363.00 and its highest was ¥724.00 in the past 12 months.

What is PhoenixBio Co., Ltd.’s market cap?

PhoenixBio Co., Ltd.’s market cap is ¥1.49B.

When is PhoenixBio Co., Ltd.’s upcoming earnings report date?

PhoenixBio Co., Ltd.’s upcoming earnings report date is Aug 19, 2026 which is in 68 days.

How were PhoenixBio Co., Ltd.’s earnings last quarter?

PhoenixBio Co., Ltd. released its earnings results on May 15, 2026. The company reported ¥7.87 earnings per share for the quarter, beating the consensus estimate of N/A by ¥7.87.

Is PhoenixBio Co., Ltd. overvalued?

According to Wall Street analysts PhoenixBio Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PhoenixBio Co., Ltd. pay dividends?

PhoenixBio Co., Ltd. does not currently pay dividends.

What is PhoenixBio Co., Ltd.’s EPS estimate?

PhoenixBio Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PhoenixBio Co., Ltd. have?

PhoenixBio Co., Ltd. has 4,076,933 shares outstanding.

What happened to PhoenixBio Co., Ltd.’s price movement after its last earnings report?

PhoenixBio Co., Ltd. reported an EPS of ¥7.87 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.778%.

Which hedge fund is a major shareholder of PhoenixBio Co., Ltd.?

Currently, no hedge funds are holding shares in JP:6190

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PhoenixBio Co., Ltd.

PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.